Chengdu Bright Eye Hospital Group Co., Ltd.

SZSE:301239 Stock Report

Market Cap: CN¥7.3b

Chengdu Bright Eye Hospital Group Future Growth

Future criteria checks 4/6

Chengdu Bright Eye Hospital Group is forecast to grow earnings and revenue by 88.5% and 18.5% per annum respectively. EPS is expected to grow by 88.6% per annum. Return on equity is forecast to be 9.5% in 3 years.

Key information

88.5%

Earnings growth rate

88.6%

EPS growth rate

Healthcare earnings growth22.9%
Revenue growth rate18.5%
Future return on equity9.5%
Analyst coverage

Low

Last updated19 Dec 2024

Recent future growth updates

No updates

Recent updates

These 4 Measures Indicate That Chengdu Bright Eye Hospital Group (SZSE:301239) Is Using Debt Extensively

Dec 17
These 4 Measures Indicate That Chengdu Bright Eye Hospital Group (SZSE:301239) Is Using Debt Extensively

After Leaping 25% Chengdu Bright Eye Hospital Group Co., Ltd. (SZSE:301239) Shares Are Not Flying Under The Radar

Nov 19
After Leaping 25% Chengdu Bright Eye Hospital Group Co., Ltd. (SZSE:301239) Shares Are Not Flying Under The Radar

Chengdu Bright Eye Hospital (SZSE:301239) Seems To Use Debt Quite Sensibly

Aug 15
Chengdu Bright Eye Hospital (SZSE:301239) Seems To Use Debt Quite Sensibly

Chengdu Bright Eye Hospital's (SZSE:301239) Upcoming Dividend Will Be Larger Than Last Year's

Jul 19
Chengdu Bright Eye Hospital's (SZSE:301239) Upcoming Dividend Will Be Larger Than Last Year's

Chengdu Bright Eye Hospital (SZSE:301239) Is Reinvesting At Lower Rates Of Return

Jul 18
Chengdu Bright Eye Hospital (SZSE:301239) Is Reinvesting At Lower Rates Of Return

Returns On Capital At Chengdu Bright Eye Hospital (SZSE:301239) Paint A Concerning Picture

Apr 11
Returns On Capital At Chengdu Bright Eye Hospital (SZSE:301239) Paint A Concerning Picture

Earnings and Revenue Growth Forecasts

SZSE:301239 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,089309N/A6952
12/31/20253,449230N/A5402
12/31/20242,90277N/A1612
9/30/20242,688-33-174481N/A
6/30/20242,76076-125542N/A
3/31/20242,7441225620N/A
12/31/20232,718268-12614N/A
9/30/20232,45924430605N/A
6/30/20232,214204-111475N/A
3/31/20231,907146-153317N/A
1/1/20231,72621-9319N/A
9/30/20221,7857028342N/A
6/30/20221,7538088340N/A
3/31/20221,75599103376N/A
1/1/20221,71094105359N/A
12/31/20201,36210981228N/A
12/31/20191,19349-141105N/A
12/31/20181,01631588N/A
12/31/2017806-13N/A27N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301239 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 301239 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 301239 is expected to become profitable in the next 3 years.

Revenue vs Market: 301239's revenue (18.5% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 301239's revenue (18.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301239's Return on Equity is forecast to be low in 3 years time (9.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:29
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chengdu Bright Eye Hospital Group Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaqi XuCitic Securities Co., Ltd.
Yuan Yuan SunIndustrial Securities Co. Ltd.